Table 1.
Up-regulated only at early stages of NASH-bound mice | Expressed in both NAFLD and NASH | Up-regulated only in NASH mice | Moderately reduced during reversal | Reduced to baseline during reversal | Suppressed in NASH and recovered during regression |
---|---|---|---|---|---|
IL28b (IFNλ3) | IL17A | KC (CXCL1) | MIG (Cxcl9) | KC (Cxcl1) | CCL11 (eotaxin) |
LIX (CXCL5) | IL23 | MIG (CXCL9) | MIP-1α (CCL3) | MCP1 (CCL2) | TNF-β |
IL31 | TNFα | IP-10 (CXCL10) | IL1β | IP-10 (CXCL10) | IL12p40 |
IL22 | VEGF | MCP1 (CCL2) | IL17A | IL9 | IL5 |
IL6 | MIP2 (CXCL2) | MIP-1α (CCL3) | IL1α | IL33 | |
IL1α | IL9 | IFNγ | LIF | ||
IL33 | IL21 | ||||
LIF | |||||
IL1β | |||||
IFNγ | |||||
Rantes |
IP-10, Interferon inducible protein 10; LIF, Leukemia inhibitory factor; MIP, Macrophage inflammatory protein; Rantes, Regulated on activation, normal T cell expressed and secreted; VEGF, vascular endothelial growth factor.